ConductScience.org, home

Paper86043

Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

van Breukelen FJ and 2 others. Lancet, 1979. Cited by 179 papers, by iCite.

Cite this record

ConductScience Library. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Papers, record 86043. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/86043

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
PubMed
Journal
Lancet
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
179
iCite
Relative citation ratio, by iCite
8
iCite
Revised in PubMed
2019-06-10
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1van Breukelen FJF J
2Bijvoet OLO L
3van Oosterom ATA T

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bone ResorptionMajor topic
DiphosphonatesMajor topic
OsteolysisMajor topic
Breast Neoplasms
Calcium
Creatinine
Female
Humans
Hydroxyproline
Hypercalcemia
Multiple Myeloma
Propanolamines

Source PubMed

Download CSV of topics

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 179 citations.

PMIDTitleJournalYearIn PapersSource
24048722Atypical femoral fractures: a review of the literature.Curr Osteoporos Rep2013https://conductscience.org/library/papers/24048722PubMed
21847749Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies.Skeletal Radiol2011https://conductscience.org/library/papers/21847749PubMed
10319239Bisphosphonate treatment of lytic bone metastases.Drugs Aging1999https://conductscience.org/library/papers/10319239PubMed
8287315Decrease of serum calcium concentration and lost influence of calcium on parathyroid hormone release in a patient with primary hyperparathyroidism after treatment with diphosphonates.Calcif Tissue Int1993https://conductscience.org/library/papers/8287315PubMed
7130396
Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
J Clin Invest1982https://conductscience.org/library/papers/7130396PubMed
6871766Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).Calcif Tissue Int1983https://conductscience.org/library/papers/6871766PubMed
6839194Structure-activity relationships of various bisphosphonates.Calcif Tissue Int1983https://conductscience.org/library/papers/6839194PubMed
6814719Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.Calcif Tissue Int1982https://conductscience.org/library/papers/6814719PubMed
6773632Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats.Calcif Tissue Int1980https://conductscience.org/library/papers/6773632PubMed
6468624The bisphosphonates HEBP and AHPrBP but not AHBP inhibit mineral mobilization and lysosomal enzyme release from mouse calvarial bones in tissue culture.Experientia1984https://conductscience.org/library/papers/6468624PubMed
6459838Human parathyroid hormone 1-34-mediated hypercalcemia in a rat model, and its inhibition by dichloromethane diphosphonate.Calcif Tissue Int1981https://conductscience.org/library/papers/6459838PubMed
6459147Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells.Calcif Tissue Int1981https://conductscience.org/library/papers/6459147PubMed
6456927The effect of diphosphonates on periosteal and bone cells in culture.Experientia1981https://conductscience.org/library/papers/6456927PubMed
6444955Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.J Clin Invest1980https://conductscience.org/library/papers/6444955PubMed
6423103Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases.Br Med J (Clin Res Ed)1984https://conductscience.org/library/papers/6423103PubMed
6423093Treatment of hypercalcaemia associated with malignancy.Br Med J (Clin Res Ed)1984https://conductscience.org/library/papers/6423093PubMed
6402083Disequilibrium hypercalcaemia.Br Med J (Clin Res Ed)1983https://conductscience.org/library/papers/6402083PubMed
6355639[Hypocalcemia in malignant diseases].Klin Wochenschr1983https://conductscience.org/library/papers/6355639PubMed
6311375The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor.Calcif Tissue Int1983https://conductscience.org/library/papers/6311375PubMed
6227496The effect of bisphosphonates on glycolysis in cultured calvaria cells and their homogenate.Experientia1983https://conductscience.org/library/papers/6227496PubMed

See all 35 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/86043

GET https://conductscience.org/api/papers/v1/86043/cited_by?page=2